EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Desmoid Tumors: Current Perspective and Treatment

Ankit Mangla, Nikki Agarwal, Gary Schwartz

Current Treatment Options in Oncology · 2024-02 · 25 (2) · 161-175

DOI: 10.1007/s11864-024-01177-5 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Treatment Options in Oncology, online erschienen am 25.01.2024. Verfasst von Ankit Mangla und 2 weiteren Autor:innen. Beteiligte Einrichtung: University Hospitals Seidman Cancer Center, Cleveland, OH, USA. axm1297@case.edu. Hauptthemen laut MEDLINE: Desmoid Tumors. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Opinion statement Desmoid tumors are rare tumors with a tendency to infiltrate locally. The lack of a standard treatment approach makes choosing the most appropriate treatment for patients challenging. Most experts recommend watchful observation for asymptomatic patients as spontaneous regression of tumor is observed in up to 20% of patients. Upfront resection of the desmoid tumor has fallen out of favor due to high morbidity and high relapse rates associated with the tumor. Systemic therapy has evolved over several decades. Where chemotherapy, hormonal therapy, and non-steroidal anti-inflammatory drugs were used over the last several decades, tyrosine kinase inhibitors came to the forefront within the last decade. Most recently, gamma-secretase inhibitors have shown significant clinical benefit in patients with desmoid tumors, bringing forth an entirely new mechanistic approach. Several Wnt pathway inhibitors are also under development. Invasive approaches like cryoablation have also shown clinical benefit in patients with extra-abdominal desmoid tumors in recent years. The recent approval of nirogacestat has ushered in a new era of treatment for patients diagnosed with desmoid tumors. Several new molecules are expected to be approved over the coming years.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Desmoid TumorsHumansRetrospective StudiesNeoplasm Recurrence, Local

Stichwörter der Autor:innen

Desmoid tumorsGamma-secretaseNirogacestatSorafenibWnt pathway

Autor:innen und Institutionen

  • University Hospitals Seidman Cancer Center, Cleveland, OH, USA. axm1297@case.edu.
  • Case Comprehensive Cancer Center, Cleveland, OH, USA. axm1297@case.edu.
  • Case Western Reserve University School of Medicine, 11100 Euclid Avenue, Lakeside Suite#1200, Room 1243, Cleveland, OH, 44106, USA. axm1297@case.edu.
  • Cleveland Clinic Children's Hospitals, Cleveland, OH, USA.
  • University Hospitals Seidman Cancer Center, Cleveland, OH, USA.
  • Case Comprehensive Cancer Center, Cleveland, OH, USA.

Zitieren

APA

Mangla, A., Agarwal, N., & Schwartz, G. (2024). Desmoid Tumors: Current Perspective and Treatment. Current Treatment Options in Oncology, 25(2), 161-175. https://doi.org/10.1007/s11864-024-01177-5

Vancouver

Mangla A, Agarwal N, Schwartz G. Desmoid Tumors: Current Perspective and Treatment. Current Treatment Options in Oncology. 2024;25(2):161-175. doi:10.1007/s11864-024-01177-5

BibTeX
@article{Mangla2024,
  author = {Mangla, Ankit and Agarwal, Nikki and Schwartz, Gary},
  title = {Desmoid Tumors: Current Perspective and Treatment},
  journal = {Current Treatment Options in Oncology},
  year = {2024},
  volume = {25},
  number = {2},
  pages = {161--175},
  doi = {10.1007/s11864-024-01177-5}
}
Kostenlos starten →